Privia Health Group's (PRVA) Market Outperform Rating Reaffirmed at JMP Securities

Privia Health Group (NASDAQ:PRVA - Get Free Report)'s stock had its "market outperform" rating reaffirmed by JMP Securities in a report released on Monday,Benzinga reports. They presently have a $29.00 target price on the stock. JMP Securities' price target indicates a potential upside of 24.36% from the company's current price.

A number of other research analysts have also recently issued reports on PRVA. Barclays lifted their target price on Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a research report on Thursday, April 10th. Robert W. Baird upped their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 15th. Canaccord Genuity Group raised their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $26.00 price target on shares of Privia Health Group in a report on Thursday, January 2nd. Finally, Needham & Company LLC reissued a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $27.38.

Privia Health Group Price Performance

NASDAQ:PRVA traded up $0.42 during mid-day trading on Monday, reaching $23.32. The stock had a trading volume of 369,530 shares, compared to its average volume of 771,494. The stock has a 50-day simple moving average of $23.50 and a two-hundred day simple moving average of $22.07. Privia Health Group has a 12 month low of $15.92 and a 12 month high of $26.04. The stock has a market capitalization of $2.83 billion, a PE ratio of 233.22, a P/E/G ratio of 3.47 and a beta of 0.88.

Insiders Place Their Bets

In related news, CFO David Mountcastle sold 3,445 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $80,371.85. Following the completion of the sale, the chief financial officer now owns 176,231 shares of the company's stock, valued at $4,111,469.23. This trade represents a 1.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Matthew Shawn Morris sold 10,309 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $240,508.97. Following the completion of the transaction, the director now directly owns 59,792 shares in the company, valued at approximately $1,394,947.36. This trade represents a 14.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,484 shares of company stock worth $799,163. Company insiders own 10.70% of the company's stock.

Institutional Investors Weigh In On Privia Health Group

Large investors have recently bought and sold shares of the stock. Barclays PLC increased its position in Privia Health Group by 240.3% in the 3rd quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after buying an additional 158,188 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Privia Health Group during the third quarter valued at approximately $263,000. Franklin Resources Inc. raised its position in shares of Privia Health Group by 2.2% during the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock worth $23,092,000 after purchasing an additional 28,480 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Privia Health Group by 8.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock worth $3,430,000 after purchasing an additional 14,641 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in Privia Health Group by 33.1% in the 4th quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock valued at $6,953,000 after purchasing an additional 86,910 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.